Related Experiment Videos
Pharmacokinetics of carbamazepine in protein energy malnutrition
Insights
Children with protein energy malnutrition (PEM) exhibit altered carbamazepine pharmacokinetics, showing reduced peak plasma levels and systemic availability. Dosage adjustments for carbamazepine in PEM may be necessary.
Area of Science:
- Pharmacokinetics
- Pediatric Nutrition
- Clinical Pharmacology
Background:
- Protein energy malnutrition (PEM) can significantly impact drug metabolism and disposition in children.
- Understanding drug pharmacokinetics in malnourished populations is crucial for effective therapeutic management.
Purpose of the Study:
- To investigate the pharmacokinetic profile of carbamazepine in children with PEM compared to healthy children.
- To determine if PEM affects the absorption, distribution, metabolism, or excretion of carbamazepine.
Main Methods:
- Enzyme multiplied immunoassay technique (EMIT) was used to quantify plasma carbamazepine concentrations.
- A single oral dose of 10 mg/kg carbamazepine was administered to both groups.
- Pharmacokinetic parameters, including peak plasma levels and area under the concentration-time curve (AUC), were analyzed.
Main Results:
- Children with PEM demonstrated significantly lower peak plasma carbamazepine levels post-administration.
- The systemic availability of carbamazepine, measured by AUC (0-48 h), was reduced in children with PEM.
- These findings suggest altered drug absorption or increased clearance in malnourished children.
Conclusions:
- Protein energy malnutrition alters carbamazepine pharmacokinetics in children.
- Reduced systemic availability of carbamazepine in PEM necessitates consideration for dose modification.
- Further studies are warranted to establish optimized dosing regimens for carbamazepine in pediatric malnutrition.
Abstract:
The pharmacokinetics of carbamazepine was studied in 6 children with protein energy malnutrition (PEM) and in 6 healthy children. Plasma carbamazepine was estimated by enzyme multiplied immunoassay technique. Single-dose concentration profiles after 10 mg/kg of the drug showed lower plasma peak levels. The systemic availability (AUC 0-48 h) of the drug in PEM was also reduced. Based on these observations, suggestions have been made for rescheduling the dosage of the drug in PEM.